3Passik SD, Messina J, Golsorkhi A, et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain[J]. J Pain Symptom Manage, 2011, 41(1):116-125.
4Roxburgh A, Bruno R, Larance B, et al. Prescription of opioid analgesics and related harms in Australia[J]. Med J Aust, 2011, 195(5):280-284.
5Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States[J]. Pain Physician, 2012, 15(3 Suppl):ES9-ES38.
6Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada:a review[J]. Pain Physician, 2012, 15(3 Suppl):ES191-ES203.
7Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone[J]. CMAJ, 2009, 181(12):891-896.
8Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure[J]. Pain, 2007, 130(1-2):144-156.
9Butler SF, Budman SH, Fanciullo GJ, et al. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy[J]. Clin J Pain, 2010, 26(9):770-776.
10Meltzer EC, Rybin D, Saitz R, et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM)[J]. Pain, 2011, 152(2):397-402.
